Profile data is unavailable for this security.
About the company
Verastem, Inc. is a late-stage development biopharmaceutical company. The Company's pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibition and focal adhesion kinase (FAK) inhibition. The Company’s advanced product candidates, avutometinib and defactinib, are being investigated in both preclinical and clinical studies for the treatment of various solid tumors, including low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer (CRC), and melanoma. Avutometinib is an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma (RAS)/RAF/MEK, ERK mitogen activated pathway kinase (MAPK) pathway. Defactinib is an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase (PYK2).
- Revenue in USD (TTM)--
- Net income in USD--
- Incorporated2010
- Employees73.00
- LocationVerastem Inc117 Kendrick Street, Suite 500CAMBRIDGE 02494United StatesUSA
- Phone+1 (781) 292-4200
- Fax+1 (302) 655-5049
- Websitehttps://www.verastem.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inozyme Pharma Inc | 0.00 | -77.11m | 280.44m | 59.00 | -- | 2.36 | -- | -- | -1.37 | -1.37 | 0.00 | 1.92 | 0.00 | -- | -- | 0.00 | -48.39 | -45.00 | -52.50 | -48.90 | -- | -- | -- | -- | -- | -- | 0.2748 | -- | -- | -- | -6.13 | -- | 2.85 | -- |
| Aquestive Therapeutics Inc | 51.50m | -28.77m | 281.31m | 135.00 | -- | -- | -- | 5.46 | -0.4273 | -0.4273 | 0.7836 | -0.4012 | 0.5398 | 2.78 | 6.49 | 381,496.30 | -30.15 | -76.63 | -43.46 | -123.85 | 60.23 | 64.24 | -55.85 | -102.95 | 5.85 | -3.51 | -- | -- | 6.09 | -5.59 | 85.54 | -- | -11.42 | -- |
| CorMedix Inc | 0.00 | -50.24m | 284.25m | 82.00 | -- | 4.90 | -- | -- | -0.9291 | -0.9291 | 0.00 | 1.06 | 0.00 | -- | -- | 0.00 | -78.96 | -54.84 | -88.88 | -62.32 | -- | 6.18 | -- | -18,323.42 | 6.41 | -- | 0.00 | -- | -100.00 | -- | -56.02 | -- | 46.27 | -- |
| Adaptimmune Therapeutics PLC - ADR | 60.28m | -113.87m | 286.23m | 449.00 | -- | 6.44 | -- | 4.75 | -0.5218 | -0.5218 | 0.2995 | 0.1739 | 0.1972 | -- | 14.60 | 134,256.10 | -37.24 | -41.19 | -48.02 | -48.21 | -- | -- | -188.90 | -714.26 | -- | -- | 0.00 | -- | 122.05 | 0.2595 | 31.18 | -- | 0.7202 | -- |
| Ventyx Biosciences Inc | 0.00 | -192.60m | 288.34m | 74.00 | -- | 0.9392 | -- | -- | -3.24 | -3.24 | 0.00 | 4.35 | 0.00 | -- | -- | 0.00 | -53.41 | -- | -55.81 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.97 | -- | -- | -- |
| Vanda Pharmaceuticals Inc. | 192.64m | 2.51m | 293.32m | 203.00 | 114.94 | 0.5322 | 53.15 | 1.52 | 0.0439 | 0.0439 | 3.35 | 9.47 | 0.3004 | 11.60 | 5.69 | 948,965.50 | 0.3912 | 6.61 | 0.4547 | 7.62 | 92.32 | 90.55 | 1.30 | 15.18 | 4.92 | -- | 0.00 | 0.00 | -24.27 | -0.0496 | -60.02 | -36.96 | -56.77 | -- |
| XOMA Corp | 5.81m | -45.09m | 295.99m | 13.00 | -- | 3.60 | -- | 50.94 | -3.92 | -3.92 | 0.5053 | 7.08 | 0.0329 | -- | 1,291.33 | 447,000.00 | -22.44 | -4.55 | -24.19 | -4.94 | -- | -- | -681.69 | -31.87 | -- | -24.55 | 0.5944 | -- | -21.06 | -2.13 | -105.10 | -- | 23.16 | -- |
| Fractyl Health Inc | 120.00k | -94.27m | 296.37m | 102.00 | -- | -- | -- | 2,469.72 | -1.97 | -1.97 | 0.0025 | -0.7881 | -- | -- | -- | 1,176.47 | -- | -- | -- | -- | 35.83 | -- | -64,242.50 | -- | 3.18 | -2.62 | 3.17 | -- | -- | -- | -48.15 | -- | -- | -- |
| Verastem Inc | -100.00bn | -100.00bn | 299.90m | 73.00 | -- | 11.97 | -- | -- | -- | -- | -- | 0.9903 | -- | -- | -- | -- | -- | -62.70 | -- | -75.18 | -- | -- | -- | -406.17 | -- | -- | 0.6208 | -- | -100.00 | -- | -18.36 | -- | -- | -- |
| Fibrobiologics Inc | 0.00 | -19.06m | 303.96m | 10.00 | -- | 241.96 | -- | -- | -0.9149 | -0.9149 | 0.00 | 0.0384 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -60.47 | 0.1012 | -- | -- | -- | -272.15 | -- | -- | -- |
| Procaps Group SA | 414.10m | 52.20m | 306.88m | 5.50k | 5.22 | 7.79 | 4.40 | 0.7411 | 0.5209 | 0.5209 | 4.16 | 0.3491 | 0.854 | 1.87 | 3.38 | 75,290.18 | 10.77 | -- | 19.01 | -- | 55.04 | -- | 12.61 | -- | 0.9861 | -- | 0.8829 | -- | 0.0434 | -- | 142.18 | -- | -- | -- |
| Nature's Sunshine Products Inc | 447.68m | 16.54m | 309.95m | 814.00 | 19.42 | 2.01 | 10.39 | 0.6924 | 0.8479 | 0.8479 | 22.96 | 8.20 | 1.86 | 1.91 | 44.39 | 549,974.20 | 7.33 | 6.57 | 10.66 | 9.41 | 72.19 | 72.69 | 3.94 | 3.74 | 1.42 | -- | 0.013 | 27.72 | 5.55 | 4.07 | 3,965.64 | -- | 16.73 | -- |
| Skye Bioscience Inc | 0.00 | -37.64m | 317.67m | 11.00 | -- | -- | -- | -- | -5.69 | -5.69 | 0.00 | -0.1726 | 0.00 | -- | -- | 0.00 | -357.65 | -232.67 | -- | -- | -- | -- | -- | -- | -- | -43.27 | 1.95 | -- | -- | -- | -93.23 | -- | 23.38 | -- |
| Rani Therapeutics Holdings Inc | 0.00 | -33.08m | 318.15m | 140.00 | -- | 41.14 | -- | -- | -1.29 | -1.29 | 0.00 | 0.1534 | 0.00 | -- | -- | 0.00 | -87.80 | -- | -140.92 | -- | -- | -- | -- | -- | -- | -28.75 | 0.6695 | -- | -- | -- | -11.06 | -- | -- | -- |
Data as of May 10 2024. Currency figures normalised to Verastem Inc's reporting currency: US Dollar USD
39.95%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Viking Global Investors LPas of 31 Dec 2023 | 2.46m | 9.71% |
| BVF Partners LPas of 31 Dec 2023 | 1.69m | 6.66% |
| Soleus Capital Management LP (Investment Management)as of 31 Dec 2023 | 1.43m | 5.64% |
| Adage Capital Management LPas of 31 Dec 2023 | 1.30m | 5.14% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.15m | 4.56% |
| Tang Capital Management LLCas of 31 Dec 2023 | 741.51k | 2.93% |
| Citadel Advisors LLCas of 31 Dec 2023 | 576.23k | 2.28% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 303.14k | 1.20% |
| Acuta Capital Partners LLCas of 31 Dec 2023 | 232.25k | 0.92% |
| Geode Capital Management LLCas of 31 Dec 2023 | 232.13k | 0.92% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
